Clinical outcomes of contemporary drug‐eluting stents in patients with and without diabetes mellitus: Multigroup propensity‐score analysis using data from stent‐specific, multicenter, prospective registries
暂无分享,去创建一个
Seung‐Jung Park | Young-Hak Kim | Duk‐Woo Park | Jung‐Min Ahn | Cheol-Whan Lee | Seung‐Whan Lee | Soo-Jin Kang | Seong-Wook Park | O. Kwon | Jung-bok Lee
[1] R. Fattori,et al. Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus. , 2017, International journal of cardiology.
[2] Samin K. Sharma,et al. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. , 2017, International journal of cardiology.
[3] P. Stella,et al. PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent. , 2016, Interventional cardiology.
[4] S. Bangalore,et al. Percutaneous Coronary Intervention in Patients With Insulin-Treated and Non-Insulin-Treated Diabetes Mellitus: Secondary Analysis of the TUXEDO Trial. , 2016, JAMA cardiology.
[5] A. Colombo,et al. Clinical outcomes of real‐world patients treated with an amphilimus polymer‐free stent versus new generation everolimus‐eluting stents , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[6] S. Bangalore,et al. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. , 2015, The New England journal of medicine.
[7] G. Stone,et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.
[8] H. Suryapranata,et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients , 2014, Open Heart.
[9] S. Bangalore,et al. Outcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Patients With Diabetes Mellitus: Can Newer Generation Drug-Eluting Stents Bridge the Gap? , 2014, Circulation. Cardiovascular interventions.
[10] I. Seong,et al. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. , 2014, JACC. Cardiovascular interventions.
[11] M. Mack,et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). , 2013, Journal of the American College of Cardiology.
[12] Lane F Burgette,et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.
[13] A. Yeung,et al. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. , 2013, JACC. Cardiovascular interventions.
[14] D. Holmes,et al. Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.
[15] J. Harnek,et al. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. , 2012, JACC. Cardiovascular interventions.
[16] A. Kirtane,et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials , 2012, BMJ : British Medical Journal.
[17] J. Suh,et al. The recanalization of chronic total occlusion leads to lumen area increase in distal reference segments in selected patients: an intravascular ultrasound study. , 2012, JACC. Cardiovascular interventions.
[18] P. Serruys,et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.
[19] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.
[20] Y. Yamori,et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the "Japanese paradox". , 2011, International journal of cardiology.
[21] P. Serruys,et al. Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus , 2011, Circulation.
[22] F. Eberli,et al. Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.
[23] P. Serruys,et al. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial , 2011, The Lancet.
[24] M. Jeong,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.
[25] B. Lagerqvist,et al. Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. , 2010 .
[26] K. Winters,et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects , 2010, European Journal of Clinical Pharmacology.
[27] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[28] J. Tardif,et al. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. , 2007, Journal of the American College of Cardiology.
[29] Seung‐Jung Park,et al. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. , 2005, The American journal of cardiology.
[30] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[31] G. Levine,et al. ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions , 2011 .